23andMe News and Activities

23andMe is a company listed under the stock ticker ME (US).

They are in:

• Biotechnology50%
• Healthcare50%

Acquisition, funding and merger involving 23andMe.

• Regeneron Pharmaceuticals has announced the acquisition of 23andMe  (posted on May 20 2025).
• 23andMe has filed for bankruptcy protection  (posted on March 25 2025).

View the org chart displaying its 24 main executives

Most searched biographies at 23andMe

• Anne Wojcicki, Chief Executive Officer
• Stephen Magowan, Director
• Janet Wojcicki, Director

Popular executive movements at 23andMe

• Hillary Aiken has joined the company as Head of Philanthropy and Development  (posted on June 19 2026).
• Kael Reicin has joined the company as Chief Financial Officer  (posted on November 14 2025).
• Stephen Quake has joined the company as Director  (posted on November 14 2025).

Click here to view some more movements at 23andMe

Create your alert
to follow the executive moves at 23andMe.

23andMe has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by 23andMe

• 23andMe Research Institute Helps Reconnect African Diaspora to Their Roots with Release of 250+ High-Resolution African Genetic Groups - 23andMe Media Center
• 23andMe Research Institute Appoints Kael Reicin as Chief Financial Officer - 23andMe Media Center
• 23andMe Research Institute Appoints Privacy Advisory Board
• 23andMe Research Institute Names Brad Margus and Stephen Quake, D.Phil., to Board of Directors
• Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community - 23andMe Media Center
• TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets | 23andMe, Inc.
• 23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation | 23andMe, Inc.
• 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process | 23andMe, Inc.
• 23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC | 23andMe, Inc.
• Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale | 23andMe, Inc.
• View more press releases Close

Social media about 23andMe

• 23andMe on Wikipedia, Google News & Yahoo Finance
• 23andMe on LinkedIn, X (Twitter) & YouTube